KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Research & Development (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 16 years of Research & Development data on record, last reported at $1.6 billion in Q4 2025.

  • For Q4 2025, Research & Development rose 15.15% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $5.5 billion, up 7.36%, while the annual FY2025 figure was $5.9 billion, 13.99% up from the prior year.
  • Research & Development reached $1.6 billion in Q4 2025 per REGN's latest filing, up from $1.4 billion in the prior quarter.
  • Across five years, Research & Development topped out at $1.6 billion in Q4 2025 and bottomed at $794.3 million in Q2 2022.
  • Average Research & Development over 4 years is $1.2 billion, with a median of $1.2 billion recorded in 2024.
  • Peak YoY movement for Research & Development: skyrocketed 36.64% in 2023, then grew 10.57% in 2024.
  • A 4-year view of Research & Development shows it stood at $794.3 million in 2022, then skyrocketed by 36.64% to $1.1 billion in 2023, then surged by 30.11% to $1.4 billion in 2024, then rose by 15.15% to $1.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $1.6 billion in Q4 2025, $1.4 billion in Q4 2024, and $1.3 billion in Q3 2024.